315 Exposé Reveals Exosome Chaos, So Young and Meituan Swiftly Remove Affected Products

Deep News03-15 23:11

A report on the March 15th China Central Television (CCTV) consumer rights day gala highlighted irregularities in the cosmetic medicine sector concerning exosome products. Currently, no exosome-based pharmaceutical products have been approved for market release in China.

In response, So Young stated that it has proactively responded to the non-compliant exosome products mentioned in the "315" gala report and has taken down the related items uploaded by merchants on its cosmetic medicine platform as a first step.

A customer service representative from Meituan said that the products involved in the report have been removed from its platform, adding that the company will actively follow the investigation's progress to protect consumer rights.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment